Back to Search
Start Over
Structure guided design and synthesis of furyl thiazolidinedione derivatives as inhibitors of GLUT 1 and GLUT 4, and evaluation of their anti-leukemic potential.
- Source :
-
European journal of medicinal chemistry [Eur J Med Chem] 2020 Sep 15; Vol. 202, pp. 112603. Date of Electronic Publication: 2020 Jul 02. - Publication Year :
- 2020
-
Abstract
- Cancer cells increase their glucose uptake and glycolytic activity to meet the high energy requirements of proliferation. Glucose transporters (GLUTs), which facilitate the transport of glucose and related hexoses across the cell membrane, play a vital role in tumor cell survival and are overexpressed in various cancers. GLUT1, the most overexpressed GLUT in many cancers, is emerging as a promising anti-cancer target. To develop GLUT1 inhibitors, we rationally designed, synthesized, structurally characterized, and biologically evaluated in-vitro and in-vivo a novel series of furyl-2-methylene thiazolidinediones (TZDs). Among 25 TZDs tested, F18 and F19 inhibited GLUT1 most potently (IC <subscript>50</subscript> 11.4 and 14.7 μM, respectively). F18 was equally selective for GLUT4 (IC <subscript>50</subscript> 6.8 μM), while F19 was specific for GLUT1 (IC <subscript>50</subscript> 152 μM in GLUT4). In-silico ligand docking studies showed that F18 interacted with conserved residues in GLUT1 and GLUT4, while F19 had slightly different interactions with the transporters. In in-vitro antiproliferative screening of leukemic/lymphoid cells, F18 was most lethal to CEM cells (CC <subscript>50</subscript> of 1.7 μM). Flow cytometry analysis indicated that F18 arrested cell cycle growth in the subG0-G1 phase and lead to cell death due to necrosis and apoptosis. Western blot analysis exhibited alterations in cell signaling proteins, consistent with cell growth arrest and death. In-vivo xenograft study in a CEM model showed that F18 impaired tumor growth significantly.<br />Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.<br /> (Copyright © 2020 Elsevier Masson SAS. All rights reserved.)
- Subjects :
- Animals
Antineoplastic Agents chemical synthesis
Antineoplastic Agents chemistry
Apoptosis drug effects
Cell Cycle drug effects
Cell Line, Tumor
Cell Proliferation drug effects
Dose-Response Relationship, Drug
Drug Screening Assays, Antitumor
Glucose Transporter Type 1 metabolism
Glucose Transporter Type 4 metabolism
Humans
Mice
Mice, SCID
Models, Molecular
Molecular Structure
Neoplasms, Experimental drug therapy
Neoplasms, Experimental metabolism
Neoplasms, Experimental pathology
Structure-Activity Relationship
Thiazolidinediones chemical synthesis
Thiazolidinediones chemistry
Antineoplastic Agents pharmacology
Drug Design
Glucose Transporter Type 1 antagonists & inhibitors
Glucose Transporter Type 4 antagonists & inhibitors
Thiazolidinediones pharmacology
Subjects
Details
- Language :
- English
- ISSN :
- 1768-3254
- Volume :
- 202
- Database :
- MEDLINE
- Journal :
- European journal of medicinal chemistry
- Publication Type :
- Academic Journal
- Accession number :
- 32634629
- Full Text :
- https://doi.org/10.1016/j.ejmech.2020.112603